Ceftazidime
Identification
- Name
- Ceftazidime
- Accession Number
- DB00438
- Description
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ceftazidime (DB00438)
- Weight
- Average: 546.576
Monoisotopic: 546.099138468 - Chemical Formula
- C22H22N6O7S2
- Synonyms
- CAZ
- Ceftazidim
- Ceftazidima
- Ceftazidime
- Ceftazidime anhydrous
- Ceftazidimum
- External IDs
- GR 20263
Pharmacology
- Indication
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
- Associated Conditions
- Bacterial Infections
- Bloodstream Infections
- Bone and Joint Infections
- Central Nervous System Infections
- Complicated Urinary Tract Infections caused by susceptible Gram-negative microorganisms
- Gynaecological infection
- Intra-Abdominal Infections
- Lower Respiratory Tract Infection (LRTI)
- Urinary Tract Infection
- Ventilator-associated Bacterial Pneumonia caused by susceptible Gram-negative microorganisms
- Hospital-acquired bacterial pneumonia caused by susceptible Gram-negative microorganisms
- Skin and skin-structure infections
- Susceptible Intra-Abdominal Infection caused by susceptible Gram-negative microorganism
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins.
- Mechanism of action
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
Target Actions Organism APeptidoglycan synthase FtsI inhibitorEscherichia coli (strain K12) APenicillin-binding protein 3 inhibitorStreptococcus pneumoniae APenicillin-binding protein 1A inhibitorEscherichia coli (strain K12) APenicillin-binding protein 1A inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1B inhibitorEscherichia coli (strain K12) APenicillin-binding protein 1B inhibitorPseudomonas aeruginosa APenicillin-binding protein 2 inhibitorPseudomonas aeruginosa APenicillin-binding protein 2 inhibitorEscherichia coli (strain K12) ND-alanyl-D-alanine endopeptidase inhibitorPseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228) - Absorption
The absorption of ceftazidime is directly proportional to the size of the dose.
- Volume of distribution
- Not Available
- Protein binding
< 10%
- Metabolism
- Not Available
- Route of elimination
The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.
- Half-life
Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.
- Clearance
- 115 mL/min
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
- Affected organisms
- Enteric bacteria and other eubacteria
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir Ceftazidime may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftazidime. Acarbose Ceftazidime may decrease the excretion rate of Acarbose which could result in a higher serum level. Aceclofenac Ceftazidime may decrease the excretion rate of Aceclofenac which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Ceftazidime is combined with Acenocoumarol. Acetaminophen Ceftazidime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Ceftazidime may decrease the excretion rate of Acetylsalicylic acid which could result in a higher serum level. Aclidinium Ceftazidime may decrease the excretion rate of Aclidinium which could result in a higher serum level. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Ceftazidime pentahydrate 9M416Z9QNR 78439-06-2 NMVPEQXCMGEDNH-TZVUEUGBSA-N Ceftazidime sodium CMC30V039K 73547-61-2 JEEWDSDYUSEQML-ROMZVAKDSA-M - International/Other Brands
- Cefzim (Pharco B International) / Ceptaz / Fortum (GlaxoSmithKline) / Tazidime / Veltadim (Novell)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataCeftazidime and Dextrose Injection, solution 1 g/50mL Intravenous B. Braun Medical Inc. 2011-06-13 Not applicable US 
Ceftazidime and Dextrose Injection, solution 2 g/50mL Intravenous B. Braun Medical Inc. 2011-06-13 Not applicable US Ceftazidime for Injection BP Powder, for solution Intravenous Sterimax Inc 2015-06-08 Not applicable Canada 
Ceftazidime for Injection BP Powder, for solution Intravenous Sterimax Inc 2015-05-29 Not applicable Canada Ceftazidime for Injection BP Powder, for solution Intramuscular; Intravenous Sterimax Inc 2015-05-28 Not applicable Canada Ceftazidime for Injection, BP Powder, for solution Intravenous Sterimax Inc 2015-06-08 Not applicable Canada Ceftazidime for Injection, USP Powder, for solution Intravenous Fresenius Kabi 1991-12-31 Not applicable Canada Ceftazidime for Injection, USP Powder, for solution Intramuscular; Intravenous Fresenius Kabi 1991-12-31 Not applicable Canada Ceftazidime for Injection, USP Powder, for solution Intravenous Fresenius Kabi 1991-12-31 Not applicable Canada Ceptaz Inj 10gm/vial Powder, for solution Intravenous Glaxo Canada Inc 1993-12-31 2001-11-07 Canada Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataCeftazidime Injection, powder, for solution 200 mg/1mL Intravenous Pfizer Laboratories, Division of Pfizer Inc 2010-05-28 2012-10-31 US Ceftazidime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Pfizer Laboratories, Division of Pfizer Inc 2010-05-28 2012-06-30 US Ceftazidime Injection, powder, for solution 2 g/1 Intravenous Sandoz 2008-05-15 Not applicable US Ceftazidime Injection, powder, for solution 6 g/100mL Intravenous WG Critical Care, LLC 2013-01-31 Not applicable US Ceftazidime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Aurobindo Pharma 2010-05-28 2012-06-30 US Ceftazidime Injection, powder, for solution 200 mg/1mL Intravenous Aurobindo Pharma 2010-05-28 2012-10-31 US Ceftazidime Injection, powder, for solution 2 g/20mL Intravenous WG Critical Care, LLC 2013-01-31 Not applicable US Ceftazidime Injection, powder, for solution 500 mg/1 Intramuscular; Intravenous Pfizer Laboratories, Division of Pfizer Inc 2010-05-28 2012-06-30 US Ceftazidime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Sandoz 2008-05-15 Not applicable US Ceftazidime Injection, powder, for solution 2 g/1 Intravenous Sagent Pharmaceuticals 2015-07-01 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Avycaz Ceftazidime pentahydrate (2 g/1) + Avibactam sodium (0.5 g/1) Powder, for solution Intravenous Allergan, Inc. 2014-12-26 Not applicable US Zavicefta Ceftazidime (2000 mg) + Avibactam (500 mg) Injection, powder, for solution Intravenous Pfizer Ireland Pharmaceuticals 2016-06-24 Not applicable EU 
Categories
- ATC Codes
- J01DD02 — Ceftazidime
- Drug Categories
- Amides
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- beta-Lactams
- Cephaloridine
- Cephalosporins
- Drugs that are Mainly Renally Excreted
- Heterocyclic Compounds, Fused-Ring
- Lactams
- Nephrotoxic agents
- OAT1/SLC22A6 inhibitors
- Sulfur Compounds
- Thiazines
- Third-Generation Cephalosporins
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporins
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / 1,3-thiazines / Pyridinium derivatives / 2-amino-1,3-thiazoles / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids show 13 more
- Substituents
- 1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin, oxime O-ether (CHEBI:3508)
Chemical Identifiers
- UNII
- DZR1ENT301
- CAS number
- 72558-82-8
- InChI Key
- ORFOPKXBNMVMKC-DWVKKRMSSA-N
- InChI
- InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
- IUPAC Name
- 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
- SMILES
- [O-]C(=O)C1=C(CS[[email protected]]2([H])[[email protected]](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1
References
- Synthesis Reference
Ronald C. Browning, Melvin G. Pleiss, Jr., "Crystallization process for ceftazidime derivative." U.S. Patent US4659813, issued May, 1982.
US4659813- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014582
- KEGG Drug
- D07654
- KEGG Compound
- C06889
- PubChem Compound
- 5481173
- PubChem Substance
- 46506143
- ChemSpider
- 4587145
- BindingDB
- 50420259
- 1545984
- ChEBI
- 3508
- ChEMBL
- CHEMBL44354
- Therapeutic Targets Database
- DAP000433
- PharmGKB
- PA448861
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ceftazidime
- AHFS Codes
- 08:12.06.12 — Third Generation Cephalosporins
- FDA label
- Download (360 KB)
- MSDS
- Download (28 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Other Cystic Fibrosis (CF) 1 4 Completed Prevention Pancreatitis 1 4 Completed Prevention Peritoneal dialysis therapy 1 4 Completed Treatment Antibiotic Reaction / Leukemias / Neutropenia, Febrile / Pediatric Cancer 1 4 Completed Treatment Infection 1 4 Completed Treatment Peritoneal Dialysis Associated Peritonitis 1 4 Terminated Treatment Cystic Fibrosis (CF) / Pseudomonas Aeruginosa / Pulmonary Exacerbation 1 4 Unknown Status Treatment Cystic Fibrosis (CF) 2 4 Unknown Status Treatment Fever / Neutropenia, Febrile 1 4 Unknown Status Treatment Infection 1
Pharmacoeconomics
- Manufacturers
- Acs dobfar spa
- Aurobindo pharma ltd
- Wockhardt ltd
- Glaxosmithkline
- Hospira inc
- Eli lilly and co
- Baxter healthcare corp
- Packagers
- Antibioticos Ltd.
- Aurobindo Pharma Ltd.
- Baxter International Inc.
- BMH Ltd.
- Cardinal Health
- GlaxoSmithKline Inc.
- Hospira Inc.
- Medisca Inc.
- Sagent Pharmaceuticals
- Sandoz
- Wockhardt Ltd.
- Dosage Forms
Form Route Strength Powder, for solution Intravenous Injection Intramuscular; Intravenous 1 gr Injection Intramuscular; Intravenous 2 gr Injection Injection, powder, for solution Injection, powder, for solution Parenteral 2 g Injection, powder, for solution Parenteral 500 mg Injection, powder, for solution Parenteral 0.5 g Injection, powder, for solution Parenteral 250 mg Injection, powder, for solution Intramuscular; Parenteral 1 G/3ML Injection, powder, for solution Intramuscular; Parenteral 250 MG/1ML Injection, powder, for solution Intramuscular; Parenteral 500 MG/1.5ML Injection, powder, for solution Intravenous; Parenteral 1 G/10ML Injection, powder, for solution Intramuscular; Parenteral 250 MG/ML Injection, powder, for solution Intramuscular; Parenteral 1 G Injection, powder, for solution Intravenous; Parenteral 1 G Powder, for solution 2 G Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 1 g/20mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, for solution Intravenous 2 g/1 Injection, powder, for solution Intravenous 2 g/20mL Injection, powder, for solution Intravenous 200 mg/1mL Injection, powder, for solution Intravenous 6 g/100mL Injection, powder, for solution Intravenous 6 g/30mL Solution / drops Ophthalmic 5 g/100mL Injection, solution Intravenous 1 g/50mL Injection, solution Intravenous 2 g/50mL Powder, for solution Intramuscular; Intravenous Powder, for solution Intravenous Injection, solution 1 g Solution / drops Auricular (otic); Ophthalmic 5 g/100mL Injection, powder, for solution Intramuscular; Intravenous 100 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 111 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 170 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 20 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 200 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 56 mg/1mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/1 Injection, solution Intravenous 20 mg/1mL Injection, solution Intravenous 40 mg/1mL Powder, for solution Intramuscular; Intravenous 1 g Powder, for solution Intravenous 2 g Powder, for solution Intravenous 6 g Injection, powder, for solution 500 mg Injection, powder, for solution 250 mg Injection, powder, for solution Parenteral 1 G Powder Intramuscular 250 MG/1ML Powder Intravenous 1 G/10ML Powder, for solution 1 G/100ML Powder, for solution 1 G Powder, for solution 2 G/100ML Injection Intravenous 0.5 g Injection Intravenous 1 g Injection Intravenous 2 g Injection, powder, for solution Intramuscular; Intravenous 500 mg Injection, powder, for solution Intravenous 1 g Injection, powder, for solution Intravenous 2 g Injection, powder, for solution Parenteral 1 G/3ML Injection, powder, for solution Parenteral 250 MG/1ML Injection, powder, for solution Parenteral 500 MG/1.5ML Injection, powder, for solution Intramuscular; Intravenous 1 g Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 6 g/1 Injection, powder, for solution 1 g Powder Intramuscular; Intravenous Injection, powder, for solution Intravenous Injection, powder, for solution Intravenous; Parenteral 2 g Injection, solution, concentrate Intravenous 500 mg Powder, for solution Intravenous 0.5 g Injection, powder, for solution 2 g Injection, powder, for solution Intramuscular; Intravenous 0.5 g - Prices
Unit description Cost Unit Fortaz 6 g/vial 150.11USD vial Ceftazidime 6 gm vial 97.05USD vial Fortaz 6 gm vial 82.8USD vial Fortaz 2 g/vial 50.01USD vial Tazicef 6 gram vial 29.88USD vial Fortaz 2 gm add-vantage vial 28.93USD vial Fortaz 2 gm vial 28.45USD vial Fortaz 1 g/vial 25.44USD vial Ceftazidime 2 gm vial 19.97USD vial Fortaz 1 gm add-vantage vial 14.71USD vial Fortaz 1 gm vial 14.23USD vial Tazicef 2 gram vial 10.66USD vial Ceftazidime 1 gm vial 10.46USD vial Ceftazidime-sodium carb powder 6.27USD g Tazicef 1 gram vial 4.57USD vial Fortaz-iso-osmot 2 gm/50 ml 0.62USD ml Fortaz-iso-osmotic 1 gm/50 ml 0.34USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region Unlock Additional DataUS7112592 No 2006-09-26 2022-02-24 US US8178554 No 2012-05-15 2021-07-24 US US7612087 No 2009-11-03 2026-11-12 US US8471025 No 2013-06-25 2031-08-12 US US8835455 No 2014-09-16 2030-10-08 US US8969566 No 2015-03-03 2032-06-15 US US9284314 No 2016-03-15 2032-06-15 US US9695122 No 2017-07-04 2032-06-15 US Additional Data Available- Filed On
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 103-113 O'Callaghan, C.H., Livermore, D.G.H. and Newall, C.E.; British Patent 2,025,398; January 23, 1980; assigned to Glaxo Group Ltd. water solubility 396 mg/L Not Available logP -1.60 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.00573 mg/mL ALOGPS logP -1.2 ALOGPS logP -4.1 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 2.77 ChemAxon pKa (Strongest Basic) 4.26 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 10 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 191.22 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 143.88 m3·mol-1 ChemAxon Polarizability 51.06 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8406 Blood Brain Barrier - 0.9857 Caco-2 permeable - 0.7235 P-glycoprotein substrate Substrate 0.8593 P-glycoprotein inhibitor I Non-inhibitor 0.8782 P-glycoprotein inhibitor II Inhibitor 0.6684 Renal organic cation transporter Non-inhibitor 0.8311 CYP450 2C9 substrate Non-substrate 0.8404 CYP450 2D6 substrate Non-substrate 0.8155 CYP450 3A4 substrate Substrate 0.5897 CYP450 1A2 substrate Non-inhibitor 0.8112 CYP450 2C9 inhibitor Non-inhibitor 0.7396 CYP450 2D6 inhibitor Non-inhibitor 0.8758 CYP450 2C19 inhibitor Non-inhibitor 0.7009 CYP450 3A4 inhibitor Non-inhibitor 0.8354 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7222 Ames test Non AMES toxic 0.7979 Carcinogenicity Non-carcinogens 0.8252 Biodegradation Not ready biodegradable 0.9951 Rat acute toxicity 1.6048 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9938 hERG inhibition (predictor II) Non-inhibitor 0.659
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peptidoglycan glycosyltransferase activity
- Specific Function
- Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
- Gene Name
- ftsI
- Uniprot ID
- P0AD68
- Uniprot Name
- Peptidoglycan synthase FtsI
- Molecular Weight
- 63876.925 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not Available
- Gene Name
- pbp3
- Uniprot ID
- Q75Y35
- Uniprot Name
- Penicillin-binding protein 3
- Molecular Weight
- 45209.84 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- mrcA
- Uniprot ID
- P02918
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 93635.545 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Cell wall formation.
- Gene Name
- pbpA
- Uniprot ID
- Q8DR59
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 79700.9 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- mrcB
- Uniprot ID
- P02919
- Uniprot Name
- Penicillin-binding protein 1B
- Molecular Weight
- 94291.875 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peptidoglycan glycosyltransferase activity
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- ponB
- Uniprot ID
- Q9X6W0
- Uniprot Name
- Penicillin-binding protein 1B
- Molecular Weight
- 85486.615 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Not Available
- Gene Name
- pbpA
- Uniprot ID
- Q9X6V3
- Uniprot Name
- Penicillin-binding protein 2
- Molecular Weight
- 72212.855 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross-linked peptidoglycan from lipid intermediates.
- Gene Name
- mrdA
- Uniprot ID
- P0AD65
- Uniprot Name
- Penicillin-binding protein 2
- Molecular Weight
- 70856.1 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation.
- Gene Name
- pbpG
- Uniprot ID
- P72161
- Uniprot Name
- D-alanyl-D-alanine endopeptidase
- Molecular Weight
- 34046.065 Da
References
- Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26. [PubMed:6413485]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [PubMed:10636865]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [PubMed:10636865]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [PubMed:10636865]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]
Drug created on June 13, 2005 07:24 / Updated on October 21, 2020 01:55
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates